ClinicalTrialsFinder
RecruitingPhase 1NCT07370155

Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers

A Phase 1, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Migaldendranib (MGB) in Healthy Volunteers

Sponsor

Ashvattha Therapeutics, Inc.

Enrollment

36 participants

Start Date

Jan 29, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteers

Summary

This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB after weekly subQ MGB administration in up to 36 healthy volunteers at 1 site in Australia.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MGB 200 mg, a drug called MGB 400 mg, and others for people with healthy volunteers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMGB 200 mg

Participants receive weekly subcutaneous administration of MGB

DRUGMGB 400 mg

Participants receive an intermediate dose of MGB administered subcutaneously once weekly

DRUGMGB 600 mg

Participants receive the highest planned dose of MGB administered subcutaneously

Locations(1)

Nucleus Network (Brisbane)

Brisbane, Queensland, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07370155

Related Trials

Sociocultural & Biobehavioral Influences on Pain Expression and Assessment

NCT032585801 location

Physical and Behavioral Traits of Overweight and Obese Adults

NCT004289871 location

Neural and Psychological Mechanisms of Pain Perception

NCT024462621 location

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

NCT077066861 location

Collection and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers

NCT004421951 location